Jack, thank you for bringing this to your audience. It is a large problem that perpetuates high drug prices. PBM's and the rebate system prevent competition and lowering of drug prices. It is not driven in the inflammatory space by drug companies. The more rheumatologist know about these issues, the better we are equipped to bring it to our representatives, patients, an other stakeholders. Great job!